1,2-Dihydro-4-quinazolinamines: Potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo

Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2003, Pages 913-916

  Tinker, Alan C ^a   Beaton, Haydn G ^a   Boughton Smith, Nigel ^a   Cook, Tony R ^a   Cooper, Sally L ^a   Fraser Rae, Lynne ^a   Hallam, Kay ^a   Hamley, Peter ^a   McInally, Tom ^a   Nicholls, David J ^a   Pimm, Austen D ^a   Wallace, Alan V ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIHYDRO 4 QUINAZOLINAMINE; 4' AMINOSPIRO[PIPERIDINE 4,2'(1'H) QUINAZOLIN] 4' AMINE; AR C 102222; AR C 85016; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME INDUCTION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; AMINES; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE; CHRONIC DISEASE; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; ISOENZYMES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; QUINAZOLINES; RATS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037435062     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0255926     Document Type: Article

References (26)

1. For reviews, see: (a) Kerwin, J. F., Jr.; Lancaster, J. R.; Feldman, P. L., Jr. Nitric Oxide: A new paradigm for second messengers. J. Med. Chem. 1995, 38, 4343-4362.
2. (b) Southan, G. J.; Szabó, C. Selective Pharmacological Inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 1996, 51, 383-394.
3. (c) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric Oxide Synthases: Structure, Function and Inhibition. Biochem. J. 2001, 357, 593-615.
4. Cochran, F. R.; Selph, J.; Sherman, P. Insights into the role of nitric oxide in inflammatory arthritis. Med. Res. Rev. 1996, 16, 547-563.
5. Boughton-Smith, N. K.; Tinker, A. C. Inhibitors of Nitric Oxide Synthase in inflammatory arthritis. IDrugs 1998, 1, 321-334.
6. G-methyl-L-arginine. Biochem. Biophys. Res. Commun. 1991, 177, 828-833.
7. G-nitroarginine. Biochemistry 1993, 32, 8512-8517.
8. G-(1-iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase. J. Med. Chem. 1994, 37, 3886-3888.
9. Ruetten, H.; Thiemermann, C.; Nitric Oxide and septic shock. In Nitric Oxide; Ignarro, L. J., Ed.; Academic Press: San Diego, 2000; pp 747-757.
10. (a) Corbett, A.; Tilton, R. G.; Chang, K.; Hasan, K. S.; Ido, Y.; Wang, J. L.; Sweetland, M. A.; Lancaster, J. R.; Williamson, J. R.; McDaniel, M. L.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992, 41, 552-556.
11. (b) Wolff, D. J.; Lubeskie, A. Aminoguanidine is an isoform selective, mechanism based inactivator of nitric oxide synthase. Arch. Biochem. Biophys. 1995, 316, 290-301.
12. Hasan, K.; Heesen, B. J.; Corbett, J. A.; McDaniel, M. L.; Chang, K.; Allison, W.; Wolfenbuttel, B. H. R.; Williamson, J. R.; Tilton, R. G. Inhibition of nitric oxide formation by guanidines. Eur. J. Pharmacol. 1993, 249, 101-106.
13. (a) Garvey E. P.; Oplinger, J. A.; Tanoury, G. J.; Sherman, P. A.; Fowler, M.; Marshall, S.; Harmon, M. F.; Paith, J. E.; Furfine, E. S. Potent and selective inhibition of human nitric oxide synthases: inhibition by non-amino acid isothioureas. J. Biol. Chem. 1994, 269, 26669-26676.
14. (b) Southan, G. J.; Szabó, C.; Thiemermann, C. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br. J. Pharmacol. 1995, 114, 510-516.
15. (a) Southan, G. J.; Szabó, C.; O'Connor, M. P.; Salzman, A. L.; Thiemermann, C. Amidines are potent inhibitors of nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur. J. Pharmacol. 1995, 291, 311-318.
16. (b) Moore, W. M.; Webber, R. K.; Fok, K. F.; Jerome, G. M.; Kornmeier, C. M.; Tjeong, F. S.; Currie M. G. Inhibitors of human nitric oxide synthase with the carbamidine moiety as a common structural element. Bioorg. Med. Chem. 1996, 4, 1559-1564.
17. (c) Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Laszlo, F.; Whittle, B. J. R.; Knowles, R. G. 1400W is a slow, tight binding inhibitor of inducible nitric oxide synthesis in vitro and in vivo. J. Biol. Chem. 1997, 21, 4959-4963.
18. Beaton, H. G.; Hamley, P.; Nicholls, D. J.; Tinker, A. C.; Wallace, A. V. 3,4-Dihydro-1-isoquinolinamines: A novel class of Nitric Oxide Synthase Inhibitors with a range of isoform selectivity and potency. Bioorg. Med. Chem. Lett. 2001, 11, 1023-1026.
19. Beaton, H. G.; Boughton-Smith, N.; Hamley, P.; Ghelani, A.; Nicholls, D. J.; Tinker, A. C.; Wallace, A. V. Thienopyridines: Nitric oxide synthase inhibitors with potent in vivo activity. Bioorg. Med. Chem. Lett. 2001, 11, 1027-1030.
20. Finch, N.; Gschwend, H. W. Rearrangement of 3-amino-1-benzylindazole to 4-amino-2-phenylquinazoline. J. Org. Chem. 1971, 36, 1463-1465.
21. Carrington, H. C. 1,2-Dihydro-2,2-dimethylquinazolines. Condensation of acetone with anthranilamide derivatives. J. Chem. Soc. 1955, 2527-2528.
22. Förstermann, U.; Schmidt, H. H. H. W.; Kohlhaas, K. L.; Murad, F. Induced RAW264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-β. Eur. J. Pharm. 1992, 225, 161-165.
23. Sherman, P. A.; Laubach, V. E.; Reep, B. R.; Wood, E. R. Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line. Biochemistry 1993, 32, 11600-11605.
24. Neither 9 nor any member of the aldehyde and ketone collection used in this experiment gave a significant inhibition of isolated i-NOS enzyme at the concentrations used in this study. (19) This enantiomer was identified as having the R-configuration from X-ray studies of enzyme inhibitor complexes (unpublished).
25. Note that the ring systems are numbered differently, such that C-5 in the quinazoline ring is spatially equivalent to C-8 of the isoquinoline.
26. Blake, D.; Mapp, P. Unpublished work.